ITP BLOCK FOR MINOR BREAST CANCER SURGERY
EU CTIS ID: 2022-501312-34-00
What this study is testing
The main objective is to determine the clinical efficacy of the intertransverse process block.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients scheduled for day case elective unilateral minor breast cancer (including DCIS) surgery
- Age ≥ 18 years at the date of inclusion
- American Associations of Anaesthesiologist (ASA) class I-III
- Have received thorough information, orally and in written form, and signed the “Informed Consent” form on participation in the study.
- Weight > 52,5 kilograms (chosen due to the maximum single dose of Ropivacaine (3mg/kg))
You likely can't join if
- Substantial co-morbidity: American Associations of Anaesthesiologist (ASA) class > III
- Any systemic muscular or neuromuscular disease
- Any use of vasodilatory substance (investigators decision)
- Local infection at the site of injection or systemic infection
- Difficult sonoanatomical visualisation of the target area (SCTL, ITTC etc.) necessary for the block execution
- Severe hypovolemia
See the full eligibility criteria
- Patients scheduled for day case elective unilateral minor breast cancer (including DCIS) surgery
- Age ≥ 18 years at the date of inclusion
- American Associations of Anaesthesiologist (ASA) class I-III
- Have received thorough information, orally and in written form, and signed the “Informed Consent” form on participation in the study.
- Weight > 52,5 kilograms (chosen due to the maximum single dose of Ropivacaine (3mg/kg))
- Substantial co-morbidity: American Associations of Anaesthesiologist (ASA) class > III
- Any systemic muscular or neuromuscular disease
- Any use of vasodilatory substance (investigators decision)
- Local infection at the site of injection or systemic infection
- Difficult sonoanatomical visualisation of the target area (SCTL, ITTC etc.) necessary for the block execution
- Severe hypovolemia
- Pregnant or breastfeeding
- Inability to speak and understand Danish
- Inability to cooperate
- Allergy to study drugs
- Daily intake of analgesics (investigators decision)
- Alcohol and/or drug overuse (investigators decision)
- Previous thoracic trauma or thoracic surgery
- Previous/current piercing of the nipple of any kind on blockade side
- Tattoos on the thorax (according to the investigators decision)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.